Matarin Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Matarin Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$423K	Sell	32,202 -27,932	-46%	-$336K	0.1%	168
2020 Q3	$581K	Buy	60,134 +28,386	+89%	+$303K	0.12%	171
2020 Q2	$363K	Buy	+31,748	New	+$359K	0.07%	180
2017 Q4	–	Sell	-38,075	Closed	-$682K	–	319
2017 Q3	$682K	Hold	38,075	–	–	0.06%	221
2017 Q2	$621K	Sell	38,075 -25,002	-40%	-$360K	0.06%	207
2017 Q1	$883K	Buy	+63,077	New	+$899K	0.09%	197

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Matarin Capital Management's VNDA Position: Q4 2020 in Review

Matarin Capital Management reduced its Vanda Pharmaceuticals (VNDA) stake by 46% in Q4 2020, selling an estimated $336K and leaving 32,202 shares worth $423K. The position accounts for 0.1% of the portfolio, ranked #168.

Matarin Capital Management first reported a position in VNDA in Q1 2017 and has held it in 6 quarters since. The position peaked at $883K in Q1 2017. 178 funds tracked by Wall St. Rank hold VNDA as of Q4 2020.

Matarin Capital Management held 32,202 shares of Vanda Pharmaceuticals worth $423K as of Q4 2020.
Matarin Capital Management sold 27,932 Vanda Pharmaceuticals shares in Q4 2020, an estimated $336K.
Vanda Pharmaceuticals made up 0.1% of Matarin Capital Management's portfolio in Q4 2020, its #168 holding.
Matarin Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2017 and has held it in 6 quarters since.
Matarin Capital Management's Vanda Pharmaceuticals position peaked at $883K in Q1 2017.
178 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.